ATG-based HLA haploidentical stem cell transplantation (HCM regimen) for recurrent or refractory round-cell-type sarcoma in AYA generation: prospective phase II study
Phase 2
- Conditions
- round-cell-type sarcoma
- Registration Number
- JPRN-UMIN000037944
- Lead Sponsor
- Division of Hematology, Department of Internal Medicine, Hyogo College of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 16
Inclusion Criteria
Not provided
Exclusion Criteria
1) serum Cre >2.0 mg/dl 2) serum T-bil >2.0 mg/dl 3) serum AST and/or ALT >200 mg/dl 4) EF <40% by ultracardiograpgy 5) SpO2 <90% in ambient air 6) PS (ECOG score) 3-4 Not always excluded if data are elevated due to original disease and are expected to improve by treatment
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method